Attached files
| file | filename |
|---|---|
| EX-10.30 - EXHIBIT 10.30 - SEELOS THERAPEUTICS, INC. | apri123117ex1030.htm |
| EX-32.1 - EXHIBIT 32.1 - SEELOS THERAPEUTICS, INC. | apri123117ex321.htm |
| EX-31.1 - EXHIBIT 31.1 - SEELOS THERAPEUTICS, INC. | apri123117ex311.htm |
| EX-21 - EXHIBIT 21 - SEELOS THERAPEUTICS, INC. | apri123117ex21.htm |
| 10-K - 10-K - SEELOS THERAPEUTICS, INC. | apri12311710k.htm |
Consent of Independent Registered Public Accounting Firm
Apricus Biosciences, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (Nos. 333-221285, 333-220624, 333-220087, 333-200799, 333-198066, 333-191679, 333-182703, 333-178592, 333-165958, 333-152591, 333-148060, 333-140110, 333-132611, 333-125565, 333-122114, 333-117717, 333-111894, 333-107137, 333-105509, 333-96813, 333-46976 and 333-91957) and Form S-8 (Nos. 333-218368, 333-215419, 333-210040, 333-204748, 333-191680, 333-182704, 333-152284, 333-138598, 333-174392, 333-167365 and 333-93435) of Apricus Biosciences, Inc. of our report dated March 1, 2018, relating to the consolidated financial statement, which appear in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
March 1, 2018